Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will release its financial results for Q1 2021 on May 10, 2021, prior to market opening. The results will be followed by a conference call at 9:00 a.m. ET to discuss financial outcomes and business highlights. Interested parties can join the call by dialing specific numbers or through a live webcast available on the company's website.
The replay will be accessible until May 16, 2021. Founded in 2007 and based in Cambridge, MA, Akebia focuses on developing therapeutics for kidney disease.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, announced that CEO John P. Butler will present at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 1:30 p.m. ET. A live webcast of the presentation will be available on the company's Investors page, with a replay accessible for 30 days post-conference. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia aims to improve the lives of those affected by kidney disease.
On April 2, 2021, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to 19 new employees totaling 131,000 shares to enhance recruitment efforts. These options have an exercise price of $3.38, the same as the stock's closing price on the grant date. Each option vests over four years, with 25% vesting after one year and the remainder quarterly, contingent on continued employment. The options adhere to Nasdaq Listing Rule 5635(c)(4) as part of the company's Inducement Award Program.
Akebia Therapeutics (Nasdaq: AKBA) announced the submission of a New Drug Application (NDA) for vadadustat, aimed at treating anemia due to chronic kidney disease (CKD) in adult patients, both on and off dialysis. The NDA encompasses data from over 8,000 patients across 36 clinical trials. The FDA has a 60-day window to assess if the NDA is acceptable for review. Further, Akebia is collaborating with Otsuka Pharmaceutical for a Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA) later this year.
Akebia Therapeutics (Nasdaq: AKBA) announced its participation in the virtual National Kidney Foundation 2021 Spring Clinical Meetings from April 6-10, 2021. The company will present new data including a poster on a Phase 1 study regarding the drug vadadustat, an investigational treatment for anemia due to chronic kidney disease (CKD). Vadadustat's global Phase 3 program is complete, although it is only approved in Japan. Akebia will also support an educational session on CKD-related anemia treatments.
Akebia Therapeutics (Nasdaq: AKBA) announced that its partner, Japan Tobacco Inc. (JT), received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) for Riona® Tablets (ferric citrate hydrate) to treat iron deficiency anemia (IDA) in adult patients in Japan. This approval follows the original marketing authorization obtained in 2014 for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients. Akebia's Auryxia® has similar indications in the U.S.
Summary not available.
On February 26, 2021, Akebia Therapeutics (Nasdaq: AKBA) granted stock options to five new employees totaling 44,000 shares as part of their employment incentives. The options were priced at $3.46 per share, matching the closing stock price on the grant date. These options will vest over four years, with 25% becoming available on the first anniversary and the remainder vesting quarterly, contingent upon continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects Akebia's commitment to attracting talent in the biopharmaceutical sector.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, announced CEO John P. Butler will participate in a fireside chat at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. This virtual event will provide insights about the company’s mission and ongoing developments. A recorded version of the presentation will be available on the company’s investor website starting March 9. Akebia, founded in 2007 and based in Cambridge, Massachusetts, aims to improve the lives of those affected by kidney disease.
Akebia Therapeutics (Nasdaq: AKBA) reported its Q4 and full-year 2020 financial results, showing total revenue of $56.7 million for Q4, a decrease from $69.6 million in Q4 2019; full-year revenue was $295.3 million, down from $335.0 million. The decline was attributed to lower collaboration revenue of $22.1 million for Q4. Akebia announced a $60 million royalty monetization transaction with HCR and aims to submit a New Drug Application for vadadustat by mid-second quarter 2021. The company's cash position was $268.7 million at year-end, expected to support operations beyond the anticipated U.S. launch of vadadustat.